Maxim downgraded Cyclo Therapeutics (CYTH) to Hold from Buy after the company entered into a definitive merger agreement with Rafael Holdings (RFL), which has agreed to acquire the company for 95c per share.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTH:
- Cyclo Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings
- Rafael Holdings, Cyclo Therapeutics enter merger agreement
- Cyclo Therapeutics reports Q2 net loss approximately $6M
- CYTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?